Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

No benefits from vitamin supplements in protection against GI cancer

A review of previously published randomized trials in this week's issue of The Lancet provides strong evidence that antioxidant supplements are not effective in protecting against gastro-intestinal cancer.

News image

fiogf49gjkf04

Researchers found that some combinations of supplements may slightly increase gastro-intestinal (GI) cancer risk, whereas selenium may be associated with a risk reduction.

The human diet is a complex mix of oxidants and antioxidants.

Excess oxidants can cause cancer by inducing gene mutations.

Goran Bjelakovic (University of Niss, Serbia and Montenegro) and colleagues from The Cochrane Hepato-Biliary Group reviewed all randomized trials comparing antioxidant supplements with placebo for prevention of gastrointestinal cancers.

The investigators identified 14 randomized trials including a total of over 170,000 participants.

Overall, the results did not show any protective effect of supplementation with -carotene, vitamins A, C, E, and selenium (alone or in combination) compared with placebo on esophageal, gastric, colorectal, pancreatic, and liver cancer incidences.

In half the trials (high quality), there was a small but statistically significant increase (6% relative risk value) in mortality among people taking antioxidants compared with placebo.

9000 in every million users of certain vitamin supplements will die prematurely
The Lancet

The results also showed that two combinations of supplements were associated with increase mortality risk: - carotene and vitamin A (30% in relative risk), and the combination of - carotene and vitamin E (10% increase in relative risk).

Four of the trials suggested that selenium was associated with a reduction in GI cancer risk, but this may be due to bias.

Dr Bjelakovic, speaking on behalf of the investigators, commented, "We could not find evidence that antioxidant supplements can prevent GI cancers; on the contrary, they seem to increase overall mortality".

"The potential preventive effect of selenium should be studied in adequate randomized trials".

David Forman (University of Leeds, UK) and Douglas Altman (Cancer Research UK) comment: "Somewhat chillingly, Bjelakovic and colleagues also estimate that, despite the small size of the relative risk, if their findings are correct, 9000 in every million users of such supplements will die prematurely as a result."

"The prospect that vitamin pills may not only do no good but also kill their consumers is a scary speculation given the vast quantities that are used in certain communities”.

However, they conclude that the findings of the study should only be viewed as preliminary.

"The mortality analysis in Bjelakovic and colleagues’ review is work in progress, and does not offer convincing proof of hazard."

"In the event that a hazard is established from a complete review, these researchers will need to identify which specific interventions are associated with any risk."

"It is unlikely that all supplements will exert a similar effect and it will be vital to establish the safety profile for those with demonstrated benefits."

The Lancet online publication October 2004
01 October 2004

Go to top of page Email this page Email this page to a colleague

 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Autoimmune pancreatitis in children
 01 November 2017 
Heartburn relief in adolescents with GERD
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us